Aclaris Therapeutics (ACRS) Q2 2026 earnings — TrendMatrix coverage
Reported
Model-generated analysis — not investment advice. Not a registered investment advisor. Past performance does not guarantee future results. How we score · Full disclosure · Editorial policy
Key numbers
- Adjusted EPS
- -$0.15
- Estimate
- -$0.15
- Surprise
- +1.9%
- Revenue (period 2026-06-30)
- $1.6M
- Score today
- 4.7/10
Revenue source: xbrl.
How the report landed
Aclaris Therapeutics (ACRS) reported adjusted EPS of -$0.15, in line with the -$0.15 estimate.
Where TrendMatrix's rating stands now
TrendMatrix currently rates ACRS Sell at 4.7/10; no pre/post engine snapshot brackets this report.
3 of the last 4 quarters beat the estimate; this quarter's +1.9% surprise compares with a +1.8% four-quarter average. Next scheduled report: 2026-11-05.
What argues against it
- Concentration risk — Counterparty: Biosion
- Quality below floor (2.1 < 4.0)
This section and the ones below it reflect TrendMatrix’s latest engine read — they update after the report date and are not frozen to it.
The levels TrendMatrix's engine tracks
- Current price
- $3.79
- Price target
- $8.86
- Stop
- $3.52
- Upside to target
- +133.8%
- Reward-to-risk
- 8.9:1
Model outputs from TrendMatrix’s engine as of 2026-10-27 — shown for context, not personalized investment advice.
ACRS at TrendMatrix's latest read
Healthcare earnings trade on pipeline and payer dynamics as much as the quarter itself; a beat or miss is weighed against trial and reimbursement news.
- Industry
- Biotechnology
- Market cap
- $557.9M
- P/E (fwd)
- -4.8
- 52-week range
- $2.10–$6.60
- Off 52-week high
- 42.6%
- RSI (14)
- 52
- Volume vs avg
- 0.40×
- Score today
- 4.7/10